3-Aminobenzamide (PARP-IN-1): Potent PARP Inhibitor Benchmarked

Executive Summary: 3-Aminobenzamide (PARP-IN-1) is a selective, nanomolar-range inhibitor of poly (ADP-ribose) polymerases (PARPs), achieving >95% inhibition at concentrations above 1 μM in CHO cells with minimal toxicity (APExBIO product information). It robustly attenuates oxidant-induced myocyte dysfunction and restores nitric oxide-mediated vasorelaxation after oxidative stress (Chempaign.net). In diabetic mouse models, it reduces albuminuria and mesangial expansion, supporting its use in diabetic nephropathy research (Pazopanib.net). The molecular weight is 136.15 Da, with high aqueous solubility and storage stability at -20°C. APExBIO provides validated workflow protocols for research purposes only.

Biological Rationale

Poly (ADP-ribose) polymerases (PARPs) are critical mediators of ADP-ribosylation, a reversible post-translational modification regulating DNA repair, cell death, and antiviral responses (Grunewald et al., 2019). Inhibition of PARP activity modulates these processes, making PARP inhibitors essential tools for studying DNA damage responses and cellular adaptation to oxidative stress. 3-Aminobenzamide (PARP-IN-1), developed and distributed by APExBIO, enables precise, reversible inhibition of PARPs in vitro and in vivo, facilitating mechanistic dissection of oxidant-induced myocyte dysfunction and endothelial dysfunction (APExBIO).

Mechanism of Action of 3-Aminobenzamide (PARP-IN-1)

3-Aminobenzamide acts as a competitive inhibitor at the NAD+ binding site of PARPs, particularly PARP1 and PARP2. It blocks the transfer of ADP-ribose from NAD+ to substrate proteins, thereby suppressing the post-translational modification known as poly (ADP-ribosyl)ation (Grunewald et al., 2019). This inhibition reduces PARP-mediated DNA repair signaling, and at high concentrations, prevents excessive poly (ADP-ribose) formation that triggers cell death pathways. In the context of viral infection, PARP inhibition has been shown to enhance viral replication and suppress interferon responses in models with defective viral macrodomains (TCS359.com), underscoring the importance of PARP activity in innate immunity. In cardiovascular and renal models, 3-Aminobenzamide's effects are attributed to reduced NAD+ consumption and preserved cellular energetics under oxidative stress.

Evidence & Benchmarks

• 3-Aminobenzamide inhibits PARP activity in CHO cells with an IC₅₀ of approximately 50 nM, and achieves >95% inhibition at >1 μM without significant toxicity (APExBIO).
• It significantly improves endothelium-dependent, nitric oxide-mediated vasorelaxation after hydrogen peroxide-induced oxidative stress (Chempaign.net).
• In diabetic db/db mouse models, 3-Aminobenzamide reduces albuminuria, mesangial expansion, and podocyte loss, demonstrating translational potential in diabetic nephropathy research (Pazopanib.net).
• PARP inhibition by 3-Aminobenzamide enhances viral replication and inhibits interferon production in coronavirus macrodomain-mutant models, confirming a role in host-pathogen interaction studies (Grunewald et al., 2019).
• The compound displays high solubility in water (≥23.45 mg/mL), ethanol (≥48.1 mg/mL), and DMSO (≥7.35 mg/mL) with sonication, supporting flexible preparation (APExBIO).

Compared to the review at Chempaign.net, which emphasizes general disease model use, this article provides updated quantitative inhibition parameters and application-specific benchmarks. Additionally, unlike the overview at Pazopanib.net, here we delineate evidence from viral immunity models and cross-reference primary mechanistic literature.

Applications, Limits & Misconceptions

3-Aminobenzamide (PARP-IN-1) is validated for the following research domains:

• Cardiac and vascular oxidative stress models: Used to dissect oxidant-induced myocyte dysfunction and to evaluate protective effects on endothelium-dependent vasorelaxation.
• Diabetic nephropathy research: Demonstrates efficacy in mouse models for reducing albuminuria and glomerular pathology.
• Host-pathogen interaction studies: Enables mechanistic exploration of PARP-mediated antiviral defense and viral macrodomain countermeasures.

Common Pitfalls or Misconceptions

• 3-Aminobenzamide is not approved for diagnostic or therapeutic use in humans; all data pertain to research contexts only (APExBIO).
• At concentrations above 10 μM, off-target effects become more likely, and results should be interpreted cautiously in long-term or high-dose studies (Chempaign.net).
• PARP inhibition may enhance viral replication in some infection models, so use in antiviral studies requires careful controls (Grunewald et al., 2019).
• Long-term storage of 3-Aminobenzamide solutions is not recommended due to potential degradation; fresh preparation is advised.
• Solubility values are dependent on pH, temperature, and sonication; always confirm solution clarity before use.

Workflow Integration & Parameters

• Stock solution preparation: Dissolve at ≥23.45 mg/mL in sterile water, ≥48.1 mg/mL in ethanol, or ≥7.35 mg/mL in DMSO using ultrasonic assistance for maximal solubility (APExBIO).
• Storage: Store solid at -20°C; freshly prepare solutions before each experiment. Do not store solutions long-term.
• Cell treatment: For optimal PARP inhibition in vitro, use final concentrations of 1–10 μM; IC₅₀ in CHO cells is ~50 nM.
• Animal models: Typical dosing regimens in mice employ 10–50 mg/kg, administered intraperitoneally, but always refer to specific study protocols for disease models (Pazopanib.net).
• Shipping: Ship on blue ice for stability; avoid repeated freeze-thaw cycles.

For advanced protocol parameters and troubleshooting, the in-depth mechanism analysis at Chempaign.net offers model-specific optimization not covered here.

Conclusion & Outlook

3-Aminobenzamide (PARP-IN-1) remains a benchmark tool for dissecting poly (ADP-ribose) polymerase function in oxidative stress, endothelial dysfunction, and diabetic nephropathy. Its nanomolar efficacy, high specificity, and excellent solubility underlie its widespread adoption in both routine and advanced research settings (APExBIO). Recent findings linking PARP inhibition to viral immune evasion (Grunewald et al., 2019) underscore the cross-domain relevance of this compound, but also highlight the need for careful application in infectious disease models. Ongoing research will further clarify optimal use conditions and define boundaries for translational application.